The trial of hydroxychloroquine as a treatment for coronavirus has been paused over safety concerns, WHO announced on Monday.

Iran Press/Europe: “The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board,” WHO Director-General Tedros Adhanom Ghebreyesus told reporters at a press briefing, reported by CNBC.

“The other arms of the trial are continuing,” Tedros said. “This concern relates to the use of hydroxychloroquine and chloroquine in COVID-19. I wish to reiterate that these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria.”

Hydroxychloroquine, which Trump has repeatedly touted as a potential game-changer in fighting the coronavirus, is an anti-malarial drug that’s also used by doctors to treat rheumatoid arthritis and lupus.

Numerous clinical trials are looking to see if it’s effective in fighting the coronavirus, but it is not a proven treatment.

But despite the lack of scientific evidence presenting hydroxychloroquine as a viable coronavirus treatment option, Trump told reporters earlier this month that he has been taking the drug to avoid contracting the disease.

The outbreak has spread to dozens of countries, with more than 5.5 million confirmed cases worldwide and over 348,000 deaths, according to data from Johns Hopkins University. There are almost 1.7 million cases in the United States and at least 99,000 deaths, according to the latest tallies.


Read More:

COVID-19 fully recovered patients exceeds 107,000: Health Min. Spox

Covid-19 patient saved by Lung transplant in Austria

Iran backs WHO program to fight against COVID-19